linjc16/ctgov huggingface dataset:
Intravenous Pantoloc In Aspirin-Induced Ulcer Bleeding

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate whether intravenous infusion of pantoprazole (Pantoloc) is effective in preventing recurrent bleeding in patients who present with acute ulcer bleeding and continue to use aspirin

Detailed Description
-----------------
Aspirin is an effective treatment for acute stroke and heart attack. However, aspirin also induces ulcer and provokes acute ulcer bleeding. Thus, aspirin is often withheld in acute ulcer bleeding but this precipitate recurrent stroke or heart attack. We previously showed that intravenous infusion of a potent acid suppressant substantially reduced the incidence of recurrent ulcer bleeding in patients who withheld aspirin. The aim of this study is to investigate whether intravenous infusion of an acid suppressant (Pantoprazole) is effective in preventing recurrent ulcer bleeding with continuous use of aspirin.

Conditions
-----------------
Cardiovascular Disease, Cerebrovascular Disorders

Intervention / Treatment
-----------------
* Drug: Aspirin and Pantoloc


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients received daily anti-platelet therapy for vascular prophylaxis before admission and will continue need to do so Patinets with bleeding peptic ulcers;ulcer actively bleeding or with SRH (Forrest I, IIa and IIb ulcers) Endoscopic haemostasis achieved Exclusion Criteria: Presence of ulcer complication precluding endoscopic treatment such as gastric outlet obstruction or ulcer perforation mandating surgical intervention. Concomitant use of anticoagulant, NSAIDs or steroid Pending to undergo cardiac interventions that need double anti-platelet agent Pregnancy Terminal illness, or cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Aspirin and Pantoloc|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary Outcome: |  |  | 
| Recurrent upper gastrointestinal bleeding within 30 days |  |  |
Human Dopamine Transported Imaging in Cocaine Abuse: 2 - 2

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the density of DA transporters during prolonged cocaine abuse and during withdrawal from cocaine use. This aim will test the hypothesis that DA transporters are altered by cocaine abuse and reestablished during withdrawal.

Official Title
-----------------
Human Dopamine Transported Imaging in Cocaine Abuse: 2

Conditions
-----------------
Cocaine-Related Disorders

Intervention / Treatment
-----------------
* Drug: Cocaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Cocaine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Psychological effects |  |  | 
| Effects of investigational drug |  |  | 
| Physiological changes in: heart rate and blood pre |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cocaine dependence
Use of Antiarrhythmic Drugs in Pediatrics

Study Overview
=================
Brief Summary
-----------------
This study aims to describe the use of Cardiovascular Drugs in Pediatrics Cardiology unit Assiut University. As regard : indications of use . proper dosage. proper management of side effects of their use.

Detailed Description
-----------------
Arrhythmias occur in children and adolescents with congenital heart disease as well as those with structurally normal hearts. Antiarrhythmic medications primarily affect the ion channels in cardiac myocytes that are responsible for generating currents that create the action potential. By altering the activity of these ion channels, the action potential is changed in an attempt to reduce the likelihood of sustained arrhythmias. There is awide range of antiarrhysmic drugs used in treatment Antiarrhysmics are therefore divided into five classes Class I: Antiarrhythmics that affect sodium channels (slow depolarization) Class II: Drugs that counteract the sympathetic nervous system, predominantly beta-blockers Class III: drugs that affect the potasium channels ( prolong repolarization) Class IV: Drugs that affect calcium channels (Calcium channel blockers) Class V: Vagotonic drugs (Digoxin) and other miscellaneous drugs

Official Title
-----------------
Adescriptive Study on the Use of Antiarrhythmic Drugs in Pediatrics Cardiology Unit Assiut University

Conditions
-----------------
Antiarrhythmic Toxicity

Intervention / Treatment
-----------------
* Drug: Antiarrhythmic drug


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All Patients with Arrhythmic cardiac diseases admitted at cardiology unit Assiut University Hospital aged from 1 month to 18 years Exclusion Criteria: ● Patients with diseases rather than arrhythmic cardiac diseases

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Antiarrhythmic drug|all classes of antiarrhythmic drugs used in pediatrics cardiology unit assiut university|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| descripe the use of antiarrhythmic drugs in pediatrics | to asses the use of antiarrhythmic drugs in cardiology unit whether its used for proper indications matching with last guidelines or not to asses also dosage (gram per Kg of weight) of each drug used .and detrimine the side effects appear and its proper management. proper dosage. proper management of side effects of their use | one year |
Beta Blockade in Critical Injury

Study Overview
=================
Brief Summary
-----------------
Critically injured patients endure a period of hypermetabolism/catabolism after being resuscitated. The metabolic cost of this may be measured in loss of lean body mass, poor wound healing, susceptibility to infection and long hospital stays. While there have been some data to suggest that hypermetabolism can be ameliorated in burn patients by beta blockade, to our knowledge, a prospective trial in trauma patients has not yet been done. Our hypothesis is that nonselective beta blockade will reduce catabolism, improve glucose control, blunt loss of lean body mass, decrease infections and improve outcome in a cohort of critically injured patients.

Official Title
-----------------
Beta-blockade Reduces Catabolism in Severely Injured Trauma Patients

Conditions
-----------------
Trauma

Intervention / Treatment
-----------------
* Drug: Propranolol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ISS>25, stable at 48 hours after injury Fully resuscitated Ventilated Exclusion Criteria Include: Intracranial hypertension requiring active treatment Hypotension/Pressors Already on beta blocker for a standard indication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Propranol Treatment<br> | Drug: Propranolol<br> <br> |
| No Intervention: Standard of Care<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in REE vs. Controls |  | ICU admission date to ICU discharge or death | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in Protein Metabolism Measurements | net nitrogen balance, fat-free mass, and fat mass | ICU admission date to ICU discharge or death | 
| Alterations in Neuroendocrine and Immunoinflammatory Measurements | blood glucose levels, insulin requirements, cortisol levels, IL-6 and IL-10 levels, infection rates, and organ dysfunction | ICU admission date to ICU discharge or death | 
| Clinical Outcome Measurements | Ventilator days, ICU and hospital days, and in-hospital mortality | ICU admission date to ICU discharge or death |
Motivational Interviewing in Physiotherapy for Patients With Low Back Pain

Study Overview
=================
Brief Summary
-----------------
This study aims to evaluate the efficacy of motivational interviewing (MI) on adherence to exercises and on levels of pain and incapacity in patients who engage in physiotherapy for low back pain. Sixty patients attending a 15-day program of physiotherapy for low back pain were allocated to experimental (EG) and control groups (CG). A regular treatment of physiotherapy with at-home exercises is offered to all participants. On day seven, MI is applied to the EG. The CG receives an anti-inflammatory information program.

Official Title
-----------------
Motivational Interviewing in Physiotherapy for Patients With Low Back Pain: Effects on Adherence to Exercises and on Levels of Incapacity and Pain

Conditions
-----------------
Motivational Interviewing

Intervention / Treatment
-----------------
* Behavioral: Motivational Interviewing
* Behavioral: Anti-inflammatory Information


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults with low back pain receiving physiotherapy with home exercises Exclusion Criteria: Adults receiving physiotherapy without home exercises or for conditions other than low back pain

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Motivational Interviewing<br> | Behavioral: Motivational Interviewing<br>* Motivation techniques<br>|
| Active Comparator: Anti-inflammatory information program<br> | Behavioral: Anti-inflammatory Information<br>* Provision of information on anti-inflammatory products<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in adherence to home exercises | At home exercises checked on the daily Table of Exercises | Change from Baseline Performance of Exercises at 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in levels of pain | Intensity of pain on the Verbal Pain Intensity Scale. Score range: none, mild, moderate, severe and maximum possible pain | Change from Baseline Levels of Pain at 2 weeks | 
| Change in levels of incapacity | Ability to conduct daily activities on the Roland-Morris Disability Questionnaire. Scores range from 0 to 24, increasing values indicating greater levels of incapacity | Change from Baseline Levels of Incapacity at 2 weeks |
Implementation of Clinical Pathway to Improve Quality of Healthcare in Stroke Inpatients

Study Overview
=================
Brief Summary
-----------------
With the extension of the average life expectancy, the incidence of cardiovascular diseases is also rising. Stroke in Taiwan has been the leading cause of morbidity and mortality, but also in countries around the world), stroke and the impact of socio-economic and health spending are large how to reduce the degree of disability after stroke is an important issue in medicine. For a long time, the resident will fill the clinical pathway form before the stroke inpatients were discharged. We also analyzed the data of clinical pathway every three months. According to the current data of stroke clinical pathway included demographic data, length of hospitalization days, complications, functional independent measure, Brunnstrom motor recovery stage, mini-mental state examination, geriatric depression scale, blood pressure data, and post-stroke checklist for a retrospective analysis to provide more complete and more comprehensive information on follow-up care for stroke patients and effective use of medical resources, to improve the quality of future medical care and quality of life for stroke patients.

Conditions
-----------------
Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ischemic and hemorrhagic stroke patients MRI confirmed the diagnosis of stroke Within three months of onset of unilateral limb hemiplegia in patients Exclusion Criteria: Initial tracheostomy impantation and hospital stay is less than 5 days Combined with other neurological diseases, such as epilepsy, multiple neuropathy, Meniere's disease, vestibular neuritis, Parkinson's disease, dementia or cerebellar atrophy, etc. Significant lesions of the lower limb joints, including joint contractures, lower limb fractures, joint replacement or long-term pain in patients with osteoarthritis Unstable signs of life (if not through the tilt bed test) or severe cardiopulmonary disease Those who can not cooperate with the study or who have not signed the inform consent

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| functional independent measurement |  | 1 year | 
| post-stroke checklist |  | 1 year | 
| Brunnstrom motor recovery stage |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stroke, clinical pathway, medical care
Project ICARE: Intervening for Community Awareness, Respect, & Empowerment

Study Overview
=================
Brief Summary
-----------------
This project will test the efficacy of a behavioral intervention to reduce sexual risk for HIV infection among African American Men who Have Sex with Men (MSM).

Official Title
-----------------
Project ICARE: Intervening for Community Awareness, Respect, & Empowerment - Behavioral Intervention to Reduce Sexual Risk Behavior of African American Men Who Have Sex With Men

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Behavioral: Project ICARE
* Behavioral: HCT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Be 18 years of age or older; Self-identify as African American Understand and read English; Live within the Chicago area; Report at least two (male or female) sex partners in the past three months, and unprotected anal sex with at least one male sex partner in the past three months. Exclusion Criteria: Have been diagnosed with HIV within the past three months (to allow for psychological and behavioral adjustment following an initial HIV diagnosis); Have a specific plan to move from the Chicago area within the next nine months; Report active injection drug use other than hormones or steroids. Participated in the intervention video or the pilot phase of this study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1: Group Intervention<br>Group level intervention | Behavioral: Project ICARE<br>* Group-level intervention (Project ICARE)<br>* Other names: Intervening for Community Awareness, Respect, & Empowerment;|
| Active Comparator: 2: HCT<br>Offer of HIV counseling and testing | Behavioral: HCT<br>* Offer of HIV counseling and testing<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Unprotected Sex |  | past three months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, Unsafe Sex, High Risk Sex, HIV Prevention, African-American, gay, bisexual, intervention trial
The Molecular Imaging Research of F-18 Labeled DX600 PET Probe

Study Overview
=================
Brief Summary
-----------------
Angiotensin-converting enzyme 2 (ACE2) plays an important role in renin-angiotensin system (RAS) and has been reported to relate with cancer. Recently, it has also been proved as the key target for COVID-19 infection. DX600 is a polypeptide that can specific binding to ACE2 specifically with nanomolar affinity reported in literature. This study constrcuted a radio-tracer, DX600 Labeled by PET Radionuclide, to monitoring biodistribution ACE2 in human beings, evaluate the detection ability of radio-tracer in ACE2 over-expression tumors and dynamic changes of ACE2 expression under therapy.

Official Title
-----------------
The Molecular Imaging Research of F-18 Labeled DX600 PET Probe

Conditions
-----------------
Solid Tumor

Intervention / Treatment
-----------------
* Other: 18F-DX600 PET/CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >3 years old; both sex; ECoG 0 or 1; Patients that would undergo biopsy or surgical operation with high ACE2 expression tumors such as colorectal cancer, renal cancer, pancreatic cancer, gastric cancer, liver cancer, lung cancer, brain cancer or suspected tumor. use 18F-FDG PET/CT as baseline evaluation Exclusion Criteria: Significant hepatic or renal dysfunction; Is Pregnant or ready to pregnant; Cannot lie on their back for half an hour; Suffering from claustrophobia or other mental diseases; Refusal to join the clinical study;

Ages Eligible for Study
-----------------
Minimum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Imaging cohort<br>All study participants will be allocated to this arm (single-arm study). Study participants will undergo 18F-DX600 PET/CT scans. | Other: 18F-DX600 PET/CT<br>* DX600, labeled with 18F will be used as a molecular imaging tracer for PET/CT scanning<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Standard uptake value (SUV) |  | 2 years |
Antimicrobial Hernia Repair Device

Study Overview
=================
Brief Summary
-----------------
This prospective early feasibility clinical study will collect information regarding the safety and efficacy of the Cook® Antimicrobial Hernia Repair Device to reinforce soft tissue during ventral or incisional hernia repair in clean-contaminated and contaminated (i.e., Class II and Class III) surgical fields.

Official Title
-----------------
Feasibility Study of the Antimicrobial Hernia Repair Device for Repair of Ventral or Incisional Hernia

Conditions
-----------------
Ventral Hernias, Incisional Hernias

Intervention / Treatment
-----------------
* Device: Antimicrobial Hernia Repair Device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with ventral or incisional hernia that is to be surgically corrected in a Class II and Class III surgical field. Exclusion Criteria: Less than 21 years old Unwilling or unable to sign and date the informed consent Pregnant, breastfeeding, or planning to become pregnant prior to completing the study Unable or unwilling to comply with follow-up schedule Simultaneously participating in another investigational drug or device study. Medical condition or disorder that would limit life expectancy to less than the primary clinical study endpoint.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Antimicrobial Hernia Repair Device<br>Antimicrobial hernia repair device for repair of ventral or incisional hernias in Class II and III surgical fields. | Device: Antimicrobial Hernia Repair Device<br>* hernia repair<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients that develop a surgical site infection | Surgical site infections (SSI) that will be included in this outcome measure are deep incisional, organ/space, and superficial incisional. | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of hernia recurrences | Hernia recurrences is the protrusion of abdominal tissue through a defect in the abdominal wall at the site of the hernia repaired during the index procedure. | 24 months | 
| Frequency of procedural and post-operative adverse events | The adverse events will be bowel erosion, bowl obstruction, delayed wound infection, fever, fistula formation, graft contraction, hernia recurrence, ileus, need for revision/resurgery, pain, premature degradation, wound dehiscence, and other wound complications. | 24 months |